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We quantified 378 HRMAS 1H NMR spectra of human brain tumours (132 glioblastomas,
101 astrocytomas, 75 meningiomas, 37 oligodendrogliomas and 33 metastases) from the
eTumour database and looked for metabolic interactions by metabolite-metabolite correla-
tion analysis (MMCA).
Results
All tumour types showed remarkably similar metabolic correlations. Lactate correlated posi-
tively with alanine, glutamate with glutamine; creatine + phosphocreatine (tCr) correlated
positively with lactate, alanine and choline + phosphocholine + glycerophosphocholine
(tCho), and tCho correlated positively with lactate; fatty acids correlated negatively with lac-
tate, glutamate + glutamine (tGlut), tCr and tCho. Oligodendrogliomas had fewer correla-
tions but they still fitted that pattern.
Conclusions
Possible explanations include (i) glycolytic tumour cells (the Warburg effect) generating
pyruvate which is converted to lactate, alanine, glutamate and then glutamine; (ii) an associ-
ation between elevated glycolysis and increased choline turnover in membranes; (iii) an
increase in the tCr pool to facilitate phosphocreatine-driven glutamate uptake; (iv) lipid
signals come from cytosolic lipid droplets in necrotic or pre-necrotic tumour tissue that
has lower concentrations of anabolic and catabolic metabolites. Additional metabolite
exchanges with host cells may also be involved. If tumours co-opt a standard set of bio-
chemical mechanisms to grow in the brain, then drugs might be developed to disrupt those
mechanisms.
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Introduction
Magnetic Resonance Spectroscopy (MRS) has been widely used for the study and characterisa-
tion of brain tumours since it can detect patterns of metabolites that are characteristic of differ-
ent tumour types. So far, the main interest has been in developing methods for improving the
sensitivity and specificity of MRI-based tumour diagnosis by including data from MRS spectra
that can be obtained non-invasively during the MRI examination. Two large European Union-
funded collaborative research programmes–INTERPRET [1] and eTumour [2]—have built up
large and publicly-accessible databases of human brain tumour spectra which can be used for
diagnostic purposes. Most of the emphasis in these programmes was on non-invasive diagno-
sis from in vivo 1H MRS spectra of the tumours that could be taken during MRI examinations,
and the algorithms developed within the INTERPRET programme for classifying those in vivo
spectra did, indeed, significantly improve radiological diagnosis of several tumour types [3].
Although the non-invasive MRS method used by INTERPRET has obvious advantages for
improving diagnosis in a clinical setting, from a scientific standpoint the number of metabolites
that can be detected is limited and their concentrations do not provide much insight into the
metabolism of the tumours. However, if a sample of the tumour is available (as is usually the case,
either from the diagnostic biopsy or from an operation specimen), then much more detailed ex
vivo 1H NMR spectra can be obtained by using the High Resolution Magic Angle Spinning
(HRMAS) method, which also has the advantage (compared with solution-state NMR methods
which involve chemical extraction of the metabolites) that it is non-destructive, so the sample is
available for other studies after the spectrum has been obtained. Such data were obtained by the
eTumour project, which followed up and extended the work of INTERPRET. It was funded
under EU Framework 6 and ran from 2004–2009, involving 20 collaborating institutions through-
out Europe and Argentina (FP6-2002-LIFESCIHEALTH 503094). MRS spectra were accrued
from more than a thousand patients including several hundred ex vivo HRMAS 1H NMR brain
tumour spectra that had been obtained from biopsies or operation specimens at 11 of the centres.
These spectra are publicly accessible (http://solaria.uab.es/eTumour/) [4] (The eTumour data base
http://solaria.uab.es/eTumour/ location has been moved and it is now available through the web-
page http://gabrmn.uab.es/), and they provide data from much larger numbers of human tumour
samples than are normally available for metabolic studies. We have utilised that eTumour
HRMAS 1H NMR database for the present study on tumour metabolism.
Metabolite assays by HRMAS 1H NMR have the advantage that all the measurements from a
specimen are obtained simultaneously with no prior derivatisation; thus one knows the relative
concentrations of both aqueous and lipophilic metabolites in that sample with high precision.
Such data are ideal for metabolite–metabolite correlation analysis (MMCA) [5–7], a method that
allows detection of interactions between the metabolites by exploiting the tiny homeostatic adjust-
ments that maintain the metabolome in a steady state. The concentrations of two metabolites will
be correlated positively if samples with a high concentration of the first metabolite also tend to
have a high concentration of the second metabolite, while samples with a low concentration for
the first metabolite also tend to have low concentrations for the second metabolite. Conversely, if
a high concentration of one metabolite in a set of samples is associated with a low concentration
of a second metabolite in the same set of samples, then that demonstrates negative correlation
between those two metabolites. Because we are concerned only with the covariation of concentra-
tions in a set of samples, MMCA can thus inform on control mechanisms within the metabolome
in tissues that were in a steady state, and there is no need to perturb them in any way.
The use of metabolite ratios between related metabolite pairs reduces the overall biological
variability in the dataset and thereby increases the statistical power. Systematic experimental
errors, such as variance in the concentration of external standards, are cancelled out in ratios,
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which reduces the overall noise in the dataset. Probably most importantly, when a metabolite pair
is connected by a biochemical pathway, metabolite ratios approximate to the corresponding reac-
tion rate under idealized steady state assumptions. Metabolite ratios then represent a biologically
most relevant entity, namely the flux through a biochemical pathway [8]. It is possible to visualize
the relations between metabolite concentrations in samples by using a scatterplot [7]. Since the
metabolites have to maintain homeostasis at all times for routine cellular functions, the plot need
not have a fixed metabolite ratio, but the values are rather scattered in the graph. Some of these
metabolite pairs can show correlations which are either positive or negative [7]. Using these pair-
wise metabolite correlations one can also construct metabolic networks[9].
Material and methods
Ethical approval: All procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national research committee and
with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent: Informed consent was obtained from all individual participants
included in the study. The eTumour project time period for recruiting the patients and collect-
ing the patient samples was from 2006 to 2009. Several centres in different countries partici-
pated in the research programme. Each centre had to ensure ethical approval by their own
local ethics committees under the local regulations.
More details can be found at http://cordis.europa.eu/resul/rcn/50778_en.html
All the HRMAS 1H NMR spectral data were downloaded from the eTumour database
(http://solaria.uab.es/eTumour/) [4]. The HRMAS 1H NMR acquisition protocol in the eTu-
mour project was designed to calibrate the 90-degree pulse for each sample and to use the
same value for all acquisition protocols of spectra on that sample. The details of all the brain
tumour samples used in this study are summarized in S1 Table. A total of 391 data samples
from the eTumour database were used: Water suppressed (acquired using the zgpr pulse
sequence in the Bruker software) spectra [total n = 378, glioblastomas (n = 132), astrocytomas
(n = 101), meningiomas (n = 75), oligodendrogliomas (n = 37) and metastases (n = 33)], T2
filtered CPMG 136 ms spectra [total n = 106, glioblastoma (n = 44), astrocytoma (n = 31),
meningioma (n = 19), oligodendrogliomas (n = 7) and metastases (n = 5)] and T2 filtered
CPMG 30 ms [total n = 391, glioblastomas (n = 143), astrocytomas (n = 100), meningiomas
(n = 76), oligodendrogliomas (n = 37) and metastases (n = 35) were downloaded and orga-
nized according to the brain tumour types that were represented. The water-suppressed spec-
tra (n = 378) were used for quantification of metabolite concentrations with LCmodel software
(version 6.3–0) (http://www.lcmodel.com/lcmodel.shtml), while the T2 filtered CPMG spectra
(n = 106 at 136 ms and n = 391 at 30 ms) were used for PCA and OPLS-DA studies. All the
spectral data analysis was performed using Bruker Topspin 3.2 processing software. The spec-
tra were Fourier transformed, phase corrected (zero and first order) and baseline corrected.
Spectral calibration was done using the chemical shift of either the creatine (3.03 ppm) or lac-
tate (1.33ppm) metabolite signals in the spectra. Spectral binning from 0.5 to 4.5 ppm in the
chemical shift region with 0.01 ppm intervals was done using the Bruker AMIX software.
Binned data were exported from text format to Microsoft Excel spreadsheets. Principle compo-
nent analysis (PCA) and orthogonal projection of latent structures–discriminant analysis
(OPLS-DA) were performed using SIMCA-14 software (Umetrics http://umetrics.com/).
Quantitative analysis
The following metabolites were quantified in the water-suppressed spectra using a modified
LCModel (version 6.3–0) basis set: alanine, choline, creatine, lactate, glutamine, glutamate,
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glycine, glycerophosphocholine, N-acetylaspartate, phosphocholine, phosphocreatine, taurine,
myo-inositol and various lipids/macromolecules [10]. The fitted values for metabolite signals
in LCModel output incorporate the content of that basis set and thus can be used for estima-
tion of metabolite concentrations and make it possible to perform MMCA. The metabolite
concentrations determined by fitting the spectra in LCModel are not absolute concentrations,
but are proportional to the concentrations of the metabolites in the LCModel basis set. To get
absolute metabolite concentrations, these LCModel output values would have to be corrected
for receiver gain and number of scans and then normalised either to trimethylsilylpropanoic
acid (TSP) or unsuppressed water. There was no TSP signal in the water-suppressed spectra,
nor was there a corresponding unsuppressed water spectrum in the eTumour database, either
of which could have yielded absolute metabolite concentrations. However, to perform MMCA
we do not need absolute concentrations, but simply a comparison (scatter plot) of two relative
metabolite concentrations, similar to a metabolite ratio. The values from LCModel fits are all
obtained from the same basis set concentrations and thus the concentration ratios from our
LCModel outputs can be compared (Dr Stephen Provencher, personal communication, 20
April 2015). Hence, we used the LCModel output values to create the pairwise metabolite scat-
ter plots.
Crame´r-Rao lower bounds (expressed herein as SD%) are widely used as a measure of the
reliability of in vivo 1H MRS of brain spectra, but there can be problems when they are used as
criteria for accepting or rejecting metabolite fittings in LCModel [11, 12]. Although most of
metabolite signals in the ex vivo HRMAS 1H NMR brain tumour spectra we studied had good
signal to noise ratios, some of them included weak signals that resulted in low values for the
metabolite peaks and Crame´r-Rao lower bounds of more than SD% = 20. Bearing in mind the
limitations of Crame´r-Rao lower bounds as an index of standard error (LCModel Manual, ver-
sion 6.3-1L, p132, 11, 12) we have not arbitrarily deleted these lower metabolite values from
our data. Instead, we have judiciously compared the signal to noise ratio, metabolite levels,
quality of spectrum and precision of the fitting of the peak (as can be seen from the residual)
in the LCModel fittings before deciding whether to exclude such data points. In practice, most
of the excluded peaks had fitted metabolite levels of either zero or close to zero and had very
high Crame´r-Rao lower bound values (SD = 999.00%). The absence of a few values in the data
does not significantly change the MMCA correlation values as they are obtained by a correla-
tion analysis method that involves robust normalisation [7, 13].
Sample weights. We also carried out sample tissue weight normalisation for LC-Model
output values and did pair-wise MMCA analysis on those values for comparison. Overall 364
datasets out of total 378 have information about the sample weight. We included this informa-
tion in detail in S1 Table.
Data normalisation for MMCA. The HRMAS 1H NMR data have a complex structure,
deriving as they do from samples acquired from biopsies or surgical specimens obtained at 11
different centres, which were then used to create HRMAS spectra using 1H NMR instruments
that operated at 500MHz or 600MHz. We have developed a mixed-model normalisation
method in order to overcome the problems of performing MMCA analysis on data types with
such complexities[13]. Metabolite levels were log-transformed and metabolites with more than
50% missing values across samples within a tumour type were excluded from the analysis.
Samples with more than 80% missing values across metabolites were also removed. A nearest
neighbour algorithm was used to impute the remaining missing values (on average ~20% of
the data). An extension of our normalization method was then used via fitting a mixed model
to the data with metabolites as fixed effects, and random effects for centre as well as separate
random sample effects for the two different NMR frequencies used. The normalized data were
extracted by using the residuals from the model with the fixed effects added, thus removing
MMCA of brain tumours
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variation induced by different centres, samples and frequencies. Pearson correlation coeffi-
cients were subsequently estimated for pairs of metabolites using the normalized data. The
correlations were filtered initially by correcting the p-values for the Pearson correlations for
multiplicity by controlling the false discovery rate using the Benjamini-Hochberg method. A
further filtering step was based on bootstrap resampling (of patient samples) in order to check
the sensitivity of the metabolite-metabolite correlations to outliers. Correlations that were
retained in the p-value filtering step but had a bootstrap confidence interval covering zero
were not considered significant. We evaluated the significance of the correlations using the fol-
lowing combinations of p-value cut-off and bootstrap confidence level: 0.001 and 0.999, 0.01
and 0.99, and 0.05 and 0.95.
For two groups of metabolites–the creatine and choline compounds–the NMR peaks could
not always be resolved. Consequently, we pooled the data for these two groups to give tCr = phos-
phocreatine + creatine, and tCho = choline + phosphocholine + glycerophosphocholine.
Although we were able to resolve the peaks of glutamate and glutamine in the HRMAS 1H NMR
spectra, we also tried combining them to give tGlut = glutamate + glutamine, as that had been
done in some earlier studies and found that this combination gave biologically interesting results.
Histopathology of samples
During the eTumour project, after the HRMAS protocol had been completed, samples had
been fixed in formalin, stained with haematoxylin and eosin and sent for histopathological
review[14]. Tumour type and grade were determined by a histopathologist. The histology was
evaluated according to the WHO 2000 classification [4] and the results were recorded in the
eTumour database, from which we downloaded them.
Results
Representative MRI and H&E sections (taken from the eTumour database) from five types of
brain tumours are shown in Fig 1. Tumour size and location in the brain can be assessed from
Fig 1. MR images and corresponding H&E sections from five types of brain tumours. The five tumour types illustrated are a glioblastoma (GBM), an
astrocytoma (AST), a meningioma (MN), an oligodendroglioma (ODG) and a metastasis (MET) from a mammary carcinoma.
https://doi.org/10.1371/journal.pone.0185980.g001
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the MR images, while H&E sections may show differences in cellularity, depending on the type
of tumour.
We first attempted to classify the data using two established methods, PCA and OPLS-DA.
Differences in the metabolite profiles of the various tumour types are clearly apparent (Fig 2)
but the PCA scores plots (S1 and S2 Figs) of the astrocytoma and meningioma samples showed
only a partial separation of the groups (bottom plots of S2 Fig). The scores plot of the astrocy-
toma and meningioma samples showed better separations in OPLS-DA with the exception of
three astrocytoma samples (S3 Fig). The cause of separation of these groups can be seen in the
loadings plot in S3 Fig: it is due to the higher metabolite signals of creatine-containing and
choline-containing compounds in astrocytomas and higher lactate signals in meningiomas.
The correlation and covariance plot (S-plot) from the OPLS-DA analysis of astrocytoma and
meningioma samples (S3 Fig) further confirmed that creatine, choline-containing metabolites
and lactate as putative biomarkers for separation of the groups. Overall, however, neither PCA
nor OPLS-DA was able to provide biochemically meaningful interpretations.
We therefore turned to the NMR-based MMCA method that we have previously described
and used to study the metabolism of cultured cells [7]. We estimated the metabolite concentra-
tions in the spectra by using LCModel, and to minimise bias caused by outliers in the data we
introduced a bootstrap filter. The highlighted squares in Fig 3 are intended to show the metab-
olite data (scatter plot, distribution and correlations) forming the basis for the colour coding
in the heatmap. For example, the first box in Fig 3, the normalized (filtered) plot of glioblas-
toma (GBM) data, highlights the metabolite correlations of lactate and alanine, whose details
Fig 2. Average HRMAS 1H NMR spectra from the five tumour types. From bottom and upwards: glioblastomas (black, n = 132), astrocytomas
(blue, n = 101), meningiomas (red, n = 75), oligodendrogliomas (brown, n = 37) and metastases (pink, n = 33).
https://doi.org/10.1371/journal.pone.0185980.g002
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are shown in the first plot in the bottom left. The plot shows the (Gaussian) distribution of the
concentrations of lactate and alanine, a scatter plot of lactate versus alanine and the correlation
coefficient (in this case 0.492, which is also given in Table 1) between lactate and alanine. This
positive correlation of lactate and alanine is represented by a red colour in the heatmap. In a
similar way a negative correlation between tGlut and lipids of 1.3ppm appears as a blue colour
Fig 3. Correlation heatmap and selected metabolite distribution summaries based on glioblastoma datasets. The correlation heatmap shown is
normalized and filtered using a p-value cut-off of 0.001 coupled to a bootstrap confidence interval of level 0.999. Metabolites are arranged according to the
main biochemical modules. The highlighted squares in the heatmap show the correlations between lactate (Lac) and alanine (Ala), glutamate (Glu) and
glutamine (Gln), as well as between tGlut (Glu+Gln) and lipid signals at 1.3ppm (Lip 13a+Lip13b).
https://doi.org/10.1371/journal.pone.0185980.g003
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in the heatmap. This is to emphasize that each box in the heatmap is constructed from the
metabolite data of 132 samples and also to show how the correlation coefficient is colour
coded in the heatmap. Heatmaps showing pairwise metabolite correlations for the other four
types of brain tumours are presented in Fig 4.
For comparison, we also performed the same analysis on data normalized for tissue weight.
The properties (median and range) of the sample weights of the five tumour types used in this
study (364 datasets out of 378 had weights available) are shown in S4A Fig. Weight-normalised
MMCA heatmaps (S4B Fig) were very similar to non-weighted MMCA heatmaps (Figs 3 and
4). We found that the correlations were quite robust with regards to weight normalisation, in
the sense that they fluctuated slightly but were not remarkably different to the correlations
observed while not compensating for tissue weight. Overall, the p-values were not remarkably
different between the two methods (S4C Fig). Hence we present and discuss non-weighted
normalised data throughout the study as it contains the data from all 378 datasets (rather than
using the reduced number of 364 weight-normalised datasets).
Table 1 shows the correlation coefficients of metabolite pairs in the main metabolic
pathways. A correlation coefficient (in absolute terms) (r) of 0.01<r<019 is regarded as a neg-
ligible correlation; 0.20<r<0.29 a weak correlation; 0.30<r<0.39 a moderate correlation;
0.40<r<0.69 a good correlation; and r>0.70 an excellent correlation. We have used these
terms in the Results section to indicate the strength of each of the correlations. Table 1 also
indicates the significance of the correlations with asterisks according to p-value cut-off and
bootstrap filtering.
Some positive correlations were observed between metabolites belonging to the same bio-
chemical pathway, but others were found between metabolites in entirely different biochemical
Table 1. Correlation coefficients of metabolite pairs across the five tumour types.
GBM AST MN ODG MET
Glycolysis Lac and Ala 0.492*** 0.429*** 0.637*** 0.199 0.458*
Lac and (Lip13a+Lip13b) -0.352** -0.498*** -0.624*** -0.545** -0.387*
Glutamine and glutamate metabolism Gln and Glu 0.579*** 0.198 0.753*** 0.111 0.426*
tGlut and Lac 0.504*** 0.634*** 0.667*** 0.515** 0.435*
tGlut and tCho 0.727*** 0.384** 0.546*** 0.214 0.401*
tGlut and (Lip1.3a+Lip1.3b) -0.604*** -0.523*** -0.661*** -0.254 -0.762***
Energy metabolism tCr and Lac 0.39*** 0.314* 0.29* 0.452* 0.242
tCr and Ala 0.27 0.211 0.388*** -0.058 0.323
tCr and tCho 0.56*** 0.336 0.295* 0.272 0.389*
tCr and (Lip1.3a+Lip1.3b) -0.719*** -0.485*** -0.555*** -0.58** -0.591**
Membrane metabolism PCho and GPC 0.023 0.043 0.726*** -0.289 NA
tCho and Lac 0.327*** 0.508*** 0.548*** 0.208 0.191
tCho and (Lip1.3a+Lip1.3b) -0.551*** -0.482*** -0.616*** -0.198 -0.492**
Lipid metabolism Lip1.3a+Lip1.3b and Lip 0.9 0.133 0.343* 0.345** 0.235 0.17
Lip1.3a+Lip1.3b and Lip 2.0 0.721*** NA 0.449*** -0.249 0.805***
GBM–glioblastoma, AST—astrocytoma, MN—meningioma, ODG- oligodendroglioma, MET—metastasis; Lac–lactate, Ala—alanine, Gln–glutamine, Glu—
glutamate, tGlut–glutamine + glutamate, GPC–glycerophosphocholine, PCho–phosphocholine, tCho–choline + phosphocholine + glycerophosphocholine,
Lip1.3a and Lip1.3b –fatty acids at 1.3ppm (fatty acids), tCr—creatine + phosphocreatine, Lip 0.9 –fatty acid at 0.9ppm (triglycerides), Lip 2.0 –fatty acid at
2.0ppm. Light blue shade in the row highlights the fatty acids that show negative correlations with metabolites.
The symbol *** represents significance under a multiplicity corrected p-value cut-off of 0.001, with an additional bootstrap filtering step using a confidence
level of 0.999, ** represents the same quantity using a cut-off of 0.01 and confidence level of 0.99, and * significance with a cut-off value of 0.05 and
confidence level of 0.95. NA–correlation not determined due to low number of values.
https://doi.org/10.1371/journal.pone.0185980.t001
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Fig 4. MMCA heatmaps based on datasets from astrocytomas, meningiomas, oligodendrogliomas and metastases. The heatmaps are
normalized and filtered using a p-value cut-off of 0.001 coupled to a bootstrap confidence interval of level 0.999. Metabolites are arranged according to the
main biochemical modules.
https://doi.org/10.1371/journal.pone.0185980.g004
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modules. In general, the correlations observed in the glioblastomas, astrocytomas, meningio-
mas and metastases were surprisingly similar. Oligodendrogliomas showed the fewest signifi-
cant correlations between the metabolites we tested (Table 1 and Fig 4D), but those few
correlations still fitted the same basic pattern observed in the other four tumour types.
In the glycolysis-associated metabolites, a good positive correlation between lactate and ala-
nine was observed in all brain tumour types except oligodendrogliomas (S5 Fig and Table 1).
In contrast, lactate showed a good to moderate negative correlation with the 1.3ppm fatty acid
peak in all the 5 tumour types.
The amino acids glutamate and glutamine showed good or excellent positive correlations in
glioblastomas, meningiomas and metastases (S6 Fig and Table 1). The combined concentra-
tions of glutamine and glutamate (tGlut) showed a good positive correlation with lactate in all
the five tumour types (S7 Fig and Table 1). The tGlut pool also showed good or excellent posi-
tive correlations with the tCho pool in glioblastomas, meningiomas and metastases, a moder-
ate correlation in astrocytomas, but only a weak correlation in oligodendrogliomas, whereas it
showed good negative correlations with the 1.3ppm fatty acid peak in all tumour types except
oligodendrogliomas (Table 1).
The tCr pool showed a good correlation with lactate in oligodendrogliomas and moderate
positive correlations with lactate in glioblastomas and astrocytomas; a weak but still statistically
significant positive correlation was observed between these metabolites in meningiomas. The
tCr pool showed a statistically significant moderate correlation with alanine only in meningio-
mas. It also correlated positively with the tCho pool in glioblastomas, meningiomas (albeit
weakly) and metastases but it correlated negatively with the 1.3ppm fatty acid peak in all
tumour types (Table 1 and S8 Fig).
Phosphocholine and glycerophosphocholine, two of the membrane-associated choline
metabolites, showed an excellent positive correlation, but only in meningiomas. The tCho
pool showed a strong positive correlation with lactate in astrocytomas and meningiomas and a
moderate but still statistically significant positive correlation in glioblastomas. In contrast, it
showed strong negative correlations with the 1.3ppm fatty acid peak in glioblastomas, astrocy-
tomas, meningiomas and metastases.
The 1.3ppm lipid signals (hereafter referred to as lipids) showed uniformly negative correla-
tions with the small-molecule metabolites involved in glycolysis (Table 1), membrane metabo-
lism (S9 Fig) energy metabolism (S10 Fig), and glutamine and glutamate metabolism (except
in oligodendrogliomas) (Table 1 and S11 Fig).
Correlations in each tumour type
Glioblastomas. The statistically significant positive correlations observed in the glioblas-
toma spectra (Table 1) are diagrammatically illustrated in Fig 5A. The three pools of metabo-
lites, tCr, tCho and tGlut, and their metabolic interconversions, are shown in dashed line
boxes. Lactate correlated positively with alanine, tCr, tCho and tGlut. The tCho pool correlated
positively with tCr and tGlut, as well as with lactate. Finally, glutamate correlated with
glutamine.
Astrocytomas. The positive correlations were generally similar in the astrocytoma spectra
(Fig 5B): lactate correlated positively with alanine, tCr, tCho and tGlut; tCho correlated posi-
tively with tGlut and with lactate. The only major differences from glioblastomas were that glu-
tamate and glutamine were not significantly correlated and nor were tCr and tCho.
Meningiomas. Positive correlations in the meningiomas followed the same general pat-
tern (Fig 5C): lactate correlated positively with alanine, tCr, tCho and tGlut, and tCho corre-
lated positively with tCr and tGlut. Like glioblastomas but unlike astrocytomas, correlations
MMCA of brain tumours
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were observed between glutamate and glutamine. In contrast to glioblastomas and astrocyto-
mas, tCr correlated positively with alanine and phosphocholine with glycerophosphocholine.
Oligodendrogliomas. The exceptions to this general pattern were the oligodendrogliomas
(Fig 5D): in those tumours, the only significant positive correlations were between lactate and
Fig 5. Illustration of the main correlations observed between metabolites across the five tumour types. Positive correlations are shown as red
arrows in (A) Glioblastomas; (B) Astrocytomas; (C) Meningiomas; (D) Oligodendrogliomas; and (E) Metastases. (F). Blue arrows indicate the negative
correlations between the soluble metabolites and the fatty acid signals that are described in the text. The same pattern was seen in all five tumour types
except for oligodendrogliomas, which did not show the correlations between fatty acids and tGlut or tCho (marked as “A” in the diagram). The metabolites
detected by HRMAS 1H NMR are shown in black with others given in grey. The dashed line boxes indicate the pools of creatine + phosphocreatine (tCr),
choline + phosphocholine + glycerophosphocholine (tCho) and glutamate + glutamine (tGlut). PtdCho indicates phosphatidylcholine in cell membranes
which is invisible to HRMAS 1H NMR.
https://doi.org/10.1371/journal.pone.0185980.g005
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tGlut and between tCr and lactate. Interestingly, however, these correlations corresponded to
the general pattern seen in the other tumour types.
Metastases. The positive correlations in the metastases showed a generally similar pattern
to those in the glioblastomas, astrocytomas and meningiomas: lactate correlated positively
with alanine and tGlut, the tCho pool correlated positively with tCr and tGlut, and glutamate
correlated with glutamine.
Overall, the positive biochemical interactions disclosed by the MMCA analysis (see Table 1
and Fig 5) were remarkably similar among four of the five brain tumour types, with oligoden-
drogliomas showing a reduced number of correlations that still followed the same general
pattern.
Negative correlations
The similarities in all the tumour types between the negative correlations of metabolites with
the fatty acids were particularly striking. The statistically significant negative correlations
observed in all the 5 tumour types are diagrammatically illustrated in Fig 5F. Fatty acids (actu-
ally the 1.3ppm peak due to the–(CH2)n- groups in fatty acids) correlated negatively with lac-
tate, tCr, tCho and tGlut in all the five tumour types, except that there was no significant
correlation between fatty acids and tGlut or tCho in oligodendrogliomas.
Discussion
NMR data have previously been extensively analysed by pattern recognition methods such as
partial least squares regression discriminant analysis (PLS-DA), PCA, and OPLS-DA in order
to distinguish normal tissues from malignant tumours and also for classifying different brain
tumour types. In vivo 1H MRS of brain metastases showed that by using the signals from lac-
tate, lipid and choline metabolites the tumours can be categorized into the early, intermediate
and late stages of metastases[15]. Creatine has been found to be useful for classifying cultured
neuronal and glial cells by pattern recognition analysis of their HRMAS 1H NMR spectral pro-
files [16]. Andronesi et al. attempted to classify brain biopsies by using a HRMAS 1H 2D-NMR
method called adiabatic TOBSY (total correlation through bond spectroscopy) which has pro-
vided enhanced sensitivity for several metabolites [17, 18]. Erb et al. used the HRMAS 1H
NMR metabolomics data from human oligodendroglioma biopsies to classify the grade of
malignancy of the tumours [19]. It has also been shown that childhood brain and nervous sys-
tem tumours can be classified by using the HRMAS 1H NMR metabolite profiles obtained
from tumour biopsies [20]. By using a bootstrap cross-validation method on in vivo 1H MRS
data of brain tumours from 35 children, medulloblastomas were characterized by high taurine,
phosphocholine and glutamate and low glutamine; astrocytomas by low creatine and high N-
acetylaspartate; and ependymomas by high myo-inositol and glycerophosphocholine [20].
Cuellar-Baena et al. have used ex vivo HRMAS 1H NMR metabolite profiles to compare paedi-
atric ependymomas, medulloblastomas and pilocytic astrocytomas and concluded that this
information may be useful for assessing tumour grade and determining optimum treatment
strategies [21].
Brain tumours are usually heterogeneous, with structures complicated by oedema and
necrosis of the adjacent parenchyma; therefore, their spectra are critically affected by voxel size
and position. However, in previous studies there was good qualitative agreement between the
in vivo 1H MRS data from human brain tumours obtained by the INTERPRET programme
and the data obtained by HRMAS 1H NMR analysis of the corresponding brain tumour biopsy
[22]. The ex vivo human glioblastoma metabolic profiles obtained in the eTumour programme
with 1D and 2D NMR methods (COSY, TOCSY and HSQC) comprehensively identified more
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than 100 resonances, and a good correlation was observed between the ex vivo and in vivo
MRS data [23]. A comparison of the in vivo 1H MRS metabolite data of brain tumours and ex
vivo HRMAS 1H NMR metabolite data from brain tumour biopsies found a good linear corre-
lation for the majority of metabolites [24]. Opstad et al. also found similar metabolic profiles
when comparing in vivo 1H MRS spectra of brain tumours and the corresponding HRMAS 1H
NMR profiles obtained from the ex vivo tumour biopsies in the eTumour programme [25].
To follow up these promising results we have used the HRMAS 1H NMR spectra from 378
human brain tumours samples available in the eTumour database. PCA and OPLS-DA analy-
sis of the spectra (obtained at echo times of both 136 ms and 30 ms) showed no clear classifica-
tion of the tumours in the scores plot (S1 and S2 Figs). Hence we estimated the metabolite
concentrations using LCModel and performed a pairwise metabolite correlation analysis [7] to
explore the latent metabolic relations in the samples from these five types of brain tumour.
Normalization and assessment of significance
We have used an established mixed model method for normalization of the complex metabo-
lite data presented in this paper[7]. Additional components to the mixed model were included
to compensate for the different NMR detection frequencies used, making it possible to include
metabolites that otherwise would be insufficiently detected at a single frequency. In addition to
multiplicity-corrected p-value filtering, a bootstrap filtering step was also employed, since esti-
mated correlation coefficients can be sensitive to outlying observations. By repeatedly sam-
pling the different spectra within each tumour type a large number of times and re-estimating
the pairwise correlations for each sample, it is possible to assess the inherent variability of the
estimated correlations that is present in the dataset. The bootstrap will, for each correlation,
produce an empirical distribution of values. If only a few (outlying) samples contribute to the
significance of a certain correlation, this distribution will have a larger spread. The corre-
sponding confidence interval created by taking selected quantiles of the bootstrap distribution
will most likely cover zero, indicating that the correlation is not significant. By bootstrap filter-
ing we add a layer of robustness to the assessment of significance. As the different tumour
types have different numbers of samples, some tumour types naturally will have more signifi-
cant correlations than others. When interpreting correlations, it is generally good to keep in
mind that although a correlation is significant, it can be of low importance if the estimated
coefficient is small.
Metabolite-metabolite correlation analysis
In our previous studies in which we developed and used an NMR-based MMCA method [7,
12] we attempted to minimise the differences between the samples by obtaining NMR spectra
from numerous identical cell cultures, all on the same NMR instrument and using the same
pulse sequence. The data for the present paper were much more varied. Spectra were obtained
at 11 different centres using 500 MHz and 600 MHz NMR instruments. Furthermore, it is
notoriously difficult to standardise the period of warm ischaemia experienced by operation
specimens before they are frozen, especially when different surgical teams and experimenters
are involved. We therefore investigated how more variable data would affect our normalization
procedure and the results from correlation analysis. When the levels of metabolites vary more
across samples, simulations indicated that we have a somewhat higher risk of false positives.
Due to these observations, we use p-values corrected for multiplicity with an extra bootstrap
filtering step added for robustness. The fact that the significant correlations observed have
plausible biochemical interpretations and seem to be consistent across most of the tumour
types, gives us confidence in the robustness of the MMCA method in this setting.
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Biochemical interpretation
Glycolytic metabolism. Some of the correlations seem to have intuitively obvious expla-
nations. For instance, in glioblastomas, astrocytomas, meningiomas and metastases there was
a positive correlation between lactate and alanine. The positive association between these two
metabolites is not surprising since they are two alternative end-products from the glycolytic
pathway. A plausible explanation (see Fig 6A) would be that in cells that are producing a large
amount of pyruvate from the glycolytic pathway it tends to be converted both to lactate by lac-
tate dehydrogenase
PyruvateþNADH! Lactateþ NADþ ð1Þ
and to alanine by alanine transaminase
Pyruvateþ Glutamate! Alanineþ a  Ketoglutarate ð2Þ
Fig 6. Diagrams illustrating biochemical mechanisms that could give rise to the observed correlations
between metabolites. (A) Glycolytic products. The enzymes driving relevant reactions are: 1, lactate dehydrogenase;
2, alanine aminotransferase; 3, glutamine synthetase; 4, glutaminase. (B) Glutaminolysis pathway to bypass PKM2
inhibition. Active enzymes are: 1, glutaminase; 2, aspartate aminotransferase; 3, malate dehydrogenase; 4, malate
decarboxylase. (C) Correlations involving the creatine pool. Dashed boxes indicate pools of metabolites: tCr, total
creatines (creatine + phosphocreatine); tCho, total cholines (choline + phosphocholine + glycerophosphocholine). The
enzyme creatine kinase is marked by the number 1. (D) Correlations involving the choline pool. Dashed boxes indicate
pools of metabolites: tCr, total creatines (creatine + phosphocreatine); tCho, total cholines (choline + phosphocholine
+ glycerophosphocholine); tGlut, glutamate + glutamine pool; PtdCho, phosphatidylcholine. The enzymes marked are:
1, choline kinase; 2, CTP:phosphocholine cytidylyltransferase and choline phosphotransferase; 3, phospholipase Al;
phospholipase A2, and lysophospholipase; 4, GPC:choline phosphodiesterase. Metabolites that were not detected by
the 1H HR-MAS NMR are shown in grey. Positive correlations are shown in red while negative correlations are in blue.
https://doi.org/10.1371/journal.pone.0185980.g006
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Thus both lactate and alanine will tend to be present in high or low concentration, all other
things (such as the presence of co-substrates necessary for the synthesis and breakdown reac-
tions) being equal. Increased alanine and lactate levels have previously been observed in brain
tumours, and they were also attributed to increased glycolysis [26].
Glutamate and glutamine metabolism. Glioblastomas, meningiomas and metastases
showed positive correlations between glutamate and glutamine signals. Since glutamine and
glutamate can be interconverted by the enzymes glutamine synthetase
Glutamateþ ATP þNH3 ! Glutamineþ ADPþ Pi ð3Þ
and glutaminase,
GlutamineþH2O! Glutamateþ NH3 ð4Þ
it is not surprising that their concentrations seem to rise and fall in unison in some tumour
types. The tGlut pool correlated positively with lactate in all tumour types, including oligoden-
drogliomas, (Fig 5A–5E) whereas in all tumour types there was a negative correlation between
tGlut and the 1.3ppm fatty acid peak (Fig 5F). The positive correlation between tGlut and lac-
tate might be connected with the positive correlation between lactate and alanine that was dis-
cussed in the previous section. Whenever a molecule of alanine is formed from pyruvate via
alanine transaminase a molecule of glutamate will be formed from α-ketoglutarate (Eq 2), and
that in turn can be converted (via glutaminase, Eq 4) into glutamine (see Fig 6A). Thus a rise
in lactate could be accompanied by a rise in tGlut and vice versa.
Rapidly proliferating cancer cells express the PKM2 isoform of the glycolytic enzyme pyru-
vate kinase. Unlike PKM1, the normal isoform, PKM2 can be inhibited, which blocks pyruvate
formation at the end of the glycolytic pathway and conserves glycolytic intermediates for anab-
olism (see Fig 6B). In these rapidly proliferating cells glutamine can be taken up and converted
first to glutamate via glutaminase
GlutamineþH2O! Glutamateþ NH3 ð5Þ
and then to α-ketoglutarate via aspartate aminotransferase
Aspartateþ a  Ketoglutarate! Oxaloacetateþ Glutamate ð6Þ
followed by a passage through part of the tricarboxylic acid cycle (TCA) to form oxaloacetate
which is converted via malate dehydrogenase and malate decarboxylase to pyruvate
Malateþ NADþ ! OxaloacetateþNADH þHþ ð7Þ
Malateþ NADþ ! Pyruvateþ CO2 þNADH þH
þ ð8Þ
which can then be converted to alanine or lactate via Eqs 1 or 2 (see Fig 6B). Once again, the
correlation between lactate and alanine can be accounted for, and in this model it is also possi-
ble to see why tGlut correlates with both lactate and alanine, since both glutamine and gluta-
mate are involved in the metabolic pathway whereby lactate and alanine can be synthesised. It
is also thought that the α-ketoglutarate formed in this pathway can pass backwards (i.e. anti-
clockwise) through the TCA to citrate which can be bled off to form fatty acids. Both lactate
and tGlut are negatively correlated with fatty acids (see Fig 6B). It is easy to see that synthesis
of lactate might be inhibited in order to increase flux towards fatty acid formation (and vice
versa) which would account for this negative correlation. It is not so easy to understand why
tGlut, a substrate of both pathways, should be positively correlated with one product, lactate,
and negatively correlated with the other, fatty acids. In reality, however, it is thought that solid
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tumours contain predominantly quiescent cancer cells and that the proliferating fraction is
quite small; thus the model illustrated in Fig 6B is likely to represent the behaviour of the main
fraction of cancer cells in the tumour and fraction of cells exhibiting the behaviour illustrated
in Fig 6B will probably be too small to influence the overall result significantly.
Choline metabolism. The choline metabolites are interconverted by a complex network
of reactions termed the Kennedy Pathway. Only three of these metabolites—choline, phospho-
choline and glycerophosphocholine—could be quantified in the brain tumour spectra, and as
their peaks could not always be resolved they are summed as the total choline pool, tCho. The
interconversions of these 3 metabolites are illustrated in Fig 6D. Choline forms phosphocho-
line via choline kinase.
Cholineþ ATP ! Phosphocholineþ ADP ð9Þ
Phosphocholine is then converted, via cytidine triphosphate:phosphocholine cytidylyltrans-
ferase and choline phosphotransferase, to phosphatidylcholine, which is the major component
of biological membranes but is not NMR-visible.
CTPþ phosphocholine!Ð pyrophosphateþ CDP  choline ð10Þ
CDP  cholineþ diacylglycerol! phosphatidylcholineþ CMP ð11Þ
Phosphatidylcholine can be broken down via phospholipase A2, and lysophospholipase to
glycerophosphocholine and then via glycerophosphocholine phosphodiesterase to choline,
thus restarting the cycle.
Phosphatidylcholine! Lysophosphatidylcholineþ Fatty Acid ð12Þ
Lysophosphatidylcholine! Glycerophosphocholineþ Fatty Acid ð13Þ
Glycerophosphocholine! Cholineþ Glycerol  3  Phosphate ð14Þ
The NMR-detectable tCho pool correlated positively with lactate, tCr and tGlut, and nega-
tively with fatty acids. These tCho pool correlations imply that the total amount of soluble
choline intermediates is biologically significant. A possible explanation for the observed corre-
lation of the size of the tCho pool with the concentrations of the metabolites in these metabolic
pathways would be that the tCho pool expands and contracts with variations in the rate of
turnover of biological membranes, and that these in turn are correlated with changes in cellu-
lar metabolism. The phosphocholine to glycerophosphocholine ratio is regarded as a marker
of malignancy[27].
Creatine metabolites. The tCr pool displayed some unexpected correlations in several of
the tumour types. It was positively correlated with lactate concentration in glioblastomas,
astrocytomas and meningiomas (Fig 5A–5C) while in oligodendrogliomas these metabolites
showed a moderate correlation that lay just outside statistical significance (p = 0.07). In menin-
giomas, alanine, another product of glycolysis, was also positively correlated with tCr (Figs 5C
and 6C). All five tumour types showed a negative correlation between the tCr pool and the
1.3ppm fatty acid signals (Figs 5F and 6C).
The metabolism of the phosphocreatine-creatine couple has been mainly studied in muscle
and to a lesser extent in the brain [28], in which phosphocreatine is thought to provide a reser-
voir of high energy phosphates that buffers the ATP pool against the sudden energy demands
created by muscle contraction or neural transmission. The phosphocreatine-creatine couple is
also thought to act as an energy shuttle [29, 30] in which the high energy phosphates of the
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ATP molecules, created at the inner mitochondrial membrane by oxidative phosphorylation,
are transferred (via creatine kinase) to creatine molecules in order to form phosphocreatine.
These phosphocreatine molecules then diffuse through the cytosol to places where ATP mole-
cules are being used in energy-requiring reactions and ADP molecules are therefore accumu-
lating. Creatine kinase then transfers the high energy phosphate of phosphocreatine to ADP,
forming ATP and allowing the energy-requiring reaction to continue.
Most previous research on phosphocreatine, either in muscle or in the brain, and whether
as an energy buffer or as an energy shuttle, has been concerned with its breakdown and resyn-
thesis, and it has been tacitly assumed that the tCr pool stays constant. The present MMCA
study challenges that assumption: we have found that the overall size of the tCr pool (i.e. the
sum of the concentrations of phosphocreatine and creatine) was positively correlated with lac-
tate concentration in three tumour types (and, alanine, another product of glycolysis, was also
positively correlated with tCr in one tumour type), suggesting that there is a hitherto unknown
mechanism linking the size of that pool with the concentrations of products of the glycolytic
pathway. Furthermore, in all five tumour types there was a negative correlation between the
tCr pool and the fatty acid signals.
It is not easy to see why a cancer cell would need phosphocreatine as a reservoir of high
energy phosphate, since (in contrast to muscles or neurons) there are no obvious situations in
which it would have to upregulate its metabolism within a matter of seconds. It also seems
unlikely that the positive correlations we observed with glycolytic products were due to phos-
phocreatine acting as a shuttle for high energy phosphates, since that would be needed in a
cancer cell that was respiring aerobically, which would mean that the glycolytic products
would have correlated negatively with tCr.
One possible explanation for these unexpected correlations would be phosphocreatine-
dependent glutamate uptake [31], which is illustrated in Fig 7. Cells that utilise such a mecha-
nism would clearly benefit from matching their tCr pool to their tGlut pool, so a positive cor-
relation would be expected. Another mechanism that might be co-opted by the cancer cells is
trafficking of lactate between tumour cells. Cancer cells in solid tumours are in symbiosis with
an extracellular milieu that includes T-cells, monocytes, dendritic cells, macrophages, endothe-
lial cells and fibroblasts among many others. Metabolites are exchanged between these cells, so
it is theoretically possible that some of the correlations we have observed arise between metab-
olite pools in different cells. Two metabolite shuttles are of particular importance in brain
tumours. The previously-mentioned phosphocreatine-dependent uptake of glutamate forms
part of a cyclic glutamate and glutamine shuttle between astrocytes and neurons in the normal
brain. It is coupled with the astrocyte-neuron lactate shuttle which supplies its energy demands
[32]. Glutamate released at the synapse (neuronal compartment) activates glutamatergic recep-
tors, and it is then taken up by the astrocytes. This will disrupt the sodium ion homeostasis in
the astrocytes, which will then be re-established by the action of sodium/potassium ATPase, an
energy-consuming process. Glutamate is converted to glutamine in astrocytes by glutamine
synthase (Eq 3), which is also an ATP-consuming process, and then it is taken up by neurons
where it is converted back to glutamate by glutaminases (Eq 4) [33]. Fig 7 shows a way in
which brain tumour cells might utilise these shuttles. If the cancer cells in a tumour co-opt the
astrocyte-neuron lactate shuttle to export their glycolytically formed lactate for oxidation in
glial cells, as shown in Fig 7, then lactate levels, which would be an aggregate concentration of
the lactate pools in the cancer cells, the extracellular space and the glial cells, might correlate
positively with the tCr levels in the cytosol of the glial cells. One normally expects cancer cells
to be forming lactate for host cells to oxidise, but Lisanti has described a “reverse Warburg
effect” in which cancer cells oxidise lactate formed in host cells [34]. In principle, either mech-
anism could result in a positive correlation between lactate and tCr.
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Lipid signal correlations. When interpreting the lipid data, it should be remembered that
the lipid signals observed in these 1H MRS spectra cannot be assigned to distinct species of
lipid molecules in the way that is possible for the water-soluble metabolites that we have quan-
tified. Instead, they arise from different types of carbon-hydrogen bond in all fatty acyl chains:
0.9ppm–CH3; 1.3ppm–(CH2)n-; 2.0ppm–CH2-CH = CH-CH2-. Thus the 1.3ppm signals, for
instance, could represent the aggregate of the–(CH2)n- groups in acyl chains of numerous dif-
ferent types of lipid molecule. The positive correlations observed between the 0.9ppm signals
and the 1.3ppm signals, and between the 1.3ppm and 2.0ppm signals probably indicate struc-
tural characteristics of fatty acid chains–e.g. that lipid molecules with–CH3 and–CH2-CH =
CH-CH2- groups also tend to have–(CH2)n- groups.
NMR-detectable lipid signals are frequently observed in all types of brain tumours both in
vivo and ex vivo, and lipid droplets are also frequently found by histology, particularly in glio-
blastomas. A strong correlation between the lipid signal at 1.3ppm and the number of lipid
droplets has been observed with Nile-red strained H&E sections in human gliomas of different
grades [35]. There was also a positive correlation between increasing necrosis in the H&E sec-
tions and the 1.3ppm fatty acid signal; larger lipid droplets were found in frankly necrotic tis-
sue but smaller ones were present in pre-necrotic tissue and the authors conclude that droplets
are initially formed in viable hypoxic tissue before necrosis and that they remain within
necrotic tissue following cell death [35]. In a rodent brain tumour model undergoing gene
Fig 7. Metabolic interactions between brain tumour cells and host cells. The lactate from tumour cell is transported to glial cells, where it is used a fuel to
produce ATP. ATP and PCr are connected via the creatine-kinase reaction. PCr, phosphocreatine; Cr, creatine; TCA, tricarboxylic acid cycle.
https://doi.org/10.1371/journal.pone.0185980.g007
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therapy, increased water diffusion was observed by 1H MRS and also accumulation of NMR vis-
ible mobile lipids due to cell death [36]. MR-detectable intra-tumoural lipids, which are mobile
lipids that accumulate in high-grade brain tumours, particularly in the necrotic regions, have
been proposed as a potential biomarker for the assessment of treatment response in cancer [37].
An unsupervised pattern recognition method used on HR-MAS spectra from human brain
metastases showed clustering due to the primary origin of the metastases, mainly based on dif-
ferences in the fatty acid signals at 1.3 and 0.9 ppm [38]. When these data were subjected to
supervised PLS-DA, spectra of the patients who had died less than 5 months after surgery
appeared to cluster together in the scores plot [38]. A positive correlation has been shown
between fatty acid signals at 1.3ppm and the number of lipid pseudo-droplets (per mm2) in
human brain tumour tissues classified as no-necrosis, low necrosis and high necrosis [35].
Cheng et al. have found that amount of lipids observed at 0.90ppm in HRMAS 1H NMR spec-
tra of glioblastoma specimens showed a positive correlation with necrosis [39]. A significant
correlation between lipid signals and necrosis in brain metastases was observed (p< 0.01),
irrespective of their primary origin. Increased polyunsaturated fatty acids (constituents of cell
and mitochondrial membranes) have been observed in gliomas during apoptosis [26]. Meta-
static melanomas showed higher amounts of glycerophosphocholine than other brain metasta-
ses [40].
A very consistent finding in the MMCA plots was the negative correlations of the 1.3ppm
fatty acid signals with lactate, tGlut, tCr and tCho (see Table 1 and Fig 4); this was observed in
four of the five tumour types, while oligodendrogliomas had significant negative correlations
of the fatty acids with lactate and tCr but not with tGlut or tCho. A possible explanation for
these almost uniform negative correlations is that the fatty acids that give rise to quantifiable
HR-MAS 1H NMR signals arise mainly from the lipid droplets that form in necrotic tissue or
pre-necrotic brain tumour tissue [27] (fatty acid components of biological membranes are
held rigidly and thus give rise to broad signals) and that tumour samples with high concentra-
tions of lipid droplets have less viable tissue containing lactate, tGlut, tCr and tCho, and vice
versa. While that sounds like a plausible explanation for the negative correlations between fatty
acids and tGlut, tCr and tCho, the negative correlation with lactate is harder to understand
since there are many reports in the literature that lactate is found along with lipids in necrotic
and pre-necrotic regions of brain tumours (most of these studies have been on gliomas) both
in vivo [41] (e.g. by MRS) and ex vivo [39]. Those papers would lead one to expect a positive
correlation between lipid and lactate signals, whereas we observed a negative correlation. We
considered the possibility that the lactate and lipid signals had been inadequately resolved in
the HRMAS 1H NMR spectra that we quantified (as can happen with in vivo MRS spectra), but
that does not appear to be the case, so we have no explanation for this apparently contradictory
result.
In general, lipids and/or lipid droplets have frequently been observed in NMR studies on
tumours and cancer cells undergoing stress, hypoxia, necrosis, apoptosis, and anti-cancer treat-
ment [26, 37]. The hypothesis that we have proposed to explain the consistently negative corre-
lations between metabolite groups and lipids that we have observed in the five types of brain
tumours—that cells with strong metabolic pathway flux (and thus high concentrations of lac-
tate, tCr, tGlut and tCho) tend not to contain NMR-visible lipid droplets, and vice versa—sug-
gests a possible mechanism for explaining the phenomena observed in earlier studies.
Is the MMCA pattern in brain tumours common to tumours in general?
This question cannot currently be answered, since to the best of our knowledge the MMCA
method has not been applied to any other type of tumour. Our previous MMCA study was
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concerned with the biochemical changes we observed in cultured human diploid fibroblasts
when they were transformed by the oncogene E1A-Ras [7]; such a transformation is a major
step on the way to creation of tumour cells. The cultured cells were chemically extracted,
which resulted in the loss of the lipid components but enabled us to detect more soluble
metabolites than is possible by HRMAS 1H NMR; for instance, we could distinguish the indi-
vidual components of the tCr and tCho pools. In order to see whether the resulting MMCA
data showed a pattern of correlations similar to that seen in the brain tumour spectra we have
combined the data from the creatines, cholines and glutamate + glutamine so as to produce
tCr, tCho and tGlut pools, and we have calculated their correlations with the other soluble
metabolites that were detected in the HRMAS 1H NMR spectra, both for the control human
diploid fibroblasts and for the E1A-Ras transformed cells (data presented in S3 Table). The
results are shown in Fig 8A and 8B; note that the fatty acids were not detected so are not
included. In the control cells (Fig 8A), lactate showed positive correlations with alanine and
tCr, and alanine also correlated positively with tCr. However, lactate was negatively rather than
positively correlated with the tGlut pool. In the E1A-Ras transformed cells we saw a very dif-
ferent pattern to that in the brain tumours (Fig 8B). Lactate still correlated positively with ala-
nine, but it correlated negatively rather than positively with tCr; furthermore, lactate correlated
negatively with tCho and tGlut, and tGlut correlated positively with tCho (Fig 8B and S3
Table). The positive correlation observed between tGlut and tCho was remarkably similar in
both the E1A-Ras transformed cells and all the brain tumour types except oligodendrogliomas
(Table 1, S3 Table, Figs 5 and 8B), indicating a strong coupling between glutaminolysis and
membrane metabolism of cells on the way to transformation and also in established malig-
nancy. In contrast, the negative correlations of lactate with tCho and tGlut observed in
E1A-Ras transformed cells were found to be positive when they were present in the brain
tumours. In the control human diploid fibroblasts, we observed positive interactions between
tCr and both lactate and alanine, similar to our results in several of the brain tumour types.
However, in the E1A-Ras transformed cells lactate correlated negatively rather than positively
with tCr. Since our previous experiment was performed in cell culture we were able to measure
Fig 8. Metabolite-Metabolite correlations in cultured human diploid fibroblasts. A). Control cells B). E1A-Ras transformed cultured cells. Data
adapted from Madhu et al [7].
https://doi.org/10.1371/journal.pone.0185980.g008
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both glucose uptake and lactate output, and both increased after E1A-Ras transformation. So
in that model, in contrast to the positive correlation observed in the brain tumours, there was
a negative correlation of lactate with tCr when the cultured cells were transformed and devel-
oped a Warburg effect.
E1A-Ras transformed cells do not display all the characteristics of cancer cells, and our
study was focussed on the immediate biochemical changes induced by transformation rather
than on long-term effects. Nevertheless, as far as they go, the results in Fig 8B do not suggest
that the constant biochemical pattern we have observed in the brain tumours is a general char-
acteristic of cancer cells.
Summary
We have found that 378 HRMAS 1H NMR spectra from five types of human brain tumour,
display a common pattern of metabolic correlations. Tumours with high levels of lactate
tended to have high levels of alanine, tCr, tGlut and tCho; conversely, tumours with high levels
of NMR-detectable fatty acids tended to have low levels of lactate, tCr, tGlut and tCho. Finally,
the creatine pool (tCr) correlated positively with lactate in three tumour types and negatively
with NMR-detectable fatty acids in all five tumour types.
We suggest that these correlations are due to the utilisation of a common set of biochemical
mechanisms by these brain tumours: (i) Tumour cells that are obtaining energy by glycolysis
convert glucose to pyruvate which can be further converted to lactate and alanine; the latter
process also forms glutamate which can be converted to glutamine. These effects also tend to
be accompanied by high concentrations of NMR-detectable choline compounds (tCho) which
could be due (ii) to an association between elevated anaerobic glycolysis and an increase in
biological membrane turnover. All these Warburg effect-associated mechanisms are negatively
correlated with high concentrations of HRMAS 1H NMR-detectable fatty acids. We suggest
that this could be because (iii) cells that are synthesising fatty acids tend not to rely on glyco-
lytic energy production and vice versa. Further sets of unexpected correlations were found
between the creatine pool (tCr) and both the glycolytic products (positive) and the fatty acids
(negative). The positive correlations between tCr and glycolytic products could be due to (iv)
the cancer cells utilising phosphocreatine-dependent glutamate uptake and/or (v) to the cancer
cells exporting lactate to oxidative host cells that utilise the creatine shuttle. Finally, (vi) we sug-
gest that cells that are forming NMR-visible lipids do not utilise phosphocreatine to take up
glutamate and vice versa.
Remarkably, the general outlines of this complex biochemical pattern were observed in all
the types of brain tumour investigated: glioblastomas, astrocytomas, meningiomas and oligo-
dendrogliomas, and in metastases from several types of primary tumour. The pattern was less
obvious in the oligodendrogliomas but some of it was still evident. The similarity in biochem-
istry between glioblastomas and astrocytomas is not entirely unexpected since they are gener-
ally thought to arise from the same type of cell, the astrocyte; indeed, some astrocytomas
develop into glioblastomas. Meningiomas, in contrast, are considered to develop from cells in
the membranes surrounding the brain, and oligodendrogliomas from cells that give rise to the
insulating sheaths of axons, so it is harder to see why they should all display similar biochemi-
cal patterns. One possible reason for the reduced number of significant correlations in the oli-
godendroglioma data is the small sample size: there were only 37 oligodendroglioma spectra
compared with 135 from glioblastomas, 101 from astrocytomas and 75 from meningiomas.
The metastases, however, displayed the common biochemical pattern more prominently than
oligodendrogliomas, although their sample size (n = 33) was even smaller; furthermore, the
metastases were derived from several different types of primary tumour (see S1 Table). In this
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context it is interesting to note that there is also a remarkable consistency between the MRS
spectra obtained in vivo from glioblastomas and MRS spectra obtained from cerebral metasta-
ses due to all types of primary tumour. Indeed it is so difficult to distinguish MRS spectra of
glioblastomas from those of metastases that special methods have been devised [42].
One possible explanation for the results reported in the present paper would be that all
these disparate brain tumour types are co-opting the same set of biochemical mechanisms–
some perhaps involving interactions with host cells—in order to grow in the specialised envi-
ronment of the brain. A possible alternative interpretation comes from recent suggestions that
the neural stem cell, astrocyte, and oligodendrocyte precursor cell can all serve as the cell of
origin for glioblastomas [43]. If it were to be found that other brain tumour types can also
arise from the same set of cell types, then that might explain why they all have such similar bio-
chemistry. However, it would not explain our observation of similar correlations in cerebral
metastases that arose from many different types of primary tumour elsewhere in the body,
which suggests that utilisation by all brain tumours of a common set of survival mechanisms is
the more likely explanation.
If the uniform set of biochemical mechanisms that we have found in many types of human
brain tumour is necessary for their growth, then it might be possible to develop novel classes
of anticancer drugs in order to disrupt those mechanisms.
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S1 Table. Details of the brain tumour datasets used in this study. Numbers of samples with
information on tissue weights are given in the brackets.
(PDF)
S2 Table. Brain tumour survival rates. Data from http://www.cancer.org/index and www.
abta.org/.
(PDF)
S3 Table. Correlation coefficients of metabolites in control and E1A/RAS treated samples.
Data adapted from ref [7].
(PDF)
S1 Fig. PCA scores and loadings plots from the data of HRMAS 1H NMR profiles (CPMG
with 136 ms). 1. Glioblastoma (green dots, n = 44), 2. Astrocytoma (violet dots, n = 31), 3.
Meningioma (red dots, n = 19), 4. Oligodendroglioma (yellow dots, n = 7) and 5. Metastasis
(blue dots, n = 5) samples.
(TIF)
S2 Fig. PCA scores and loadings plots from the data of HRMAS 1H NMR profiles (CPMG
with 30 ms). 1. Glioblastomas (green dots, n = 145), 2. Astrocytoma (violet dots, n = 101), 3.
Meningioma (red dots, n = 75), 4. Oligodendroglioma (yellow dots, n = 37) and 5. Metastasis
(blue dots, n = 33).
(TIF)
S3 Fig. OPLS-DA of HRMAS 1H NMR profiles (CPMG with 30 ms) data. Astrocytoma (vio-
let dots, n = 101), Meningioma (red dots, n = 75) samples.
(TIF)
S4 Fig. Summary of analysis on tissue weighted data. (A) Boxplots illustrating the median
and range for tissue weights across the five different tumour types. (B) MMCA heatmaps
based on the tissue normalised data from the five tumour types. (C) Comparison of non-
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weighted and weighted correlation coefficients and p-values across the five tumour types. The
heatmaps were filtered using a p-value cut-off of 0.001 coupled to a bootstrap confidence inter-
val of level 0.999.
(PDF)
S5 Fig. Correlations observed between glycolytic pathway products (Lac and Ala) across
the five different tumour types.
(TIF)
S6 Fig. Correlations observed between glutamine (Gln) and glutamate (Glu) across the five
different tumour types.
(TIF)
S7 Fig. Correlations observed between tGlut (glutamate + glutamine) content and lactate
across the five different tumour types.
(TIF)
S8 Fig. Correlations between energy metabolism (tCr) and membrane metabolism (tCho)
across the five different tumour types.
(TIF)
S9 Fig. Correlations between membrane metabolites (tCho) and lipids at 1.30 ppm across
the five different tumour types.
(TIF)
S10 Fig. Correlation between energy metabolites (tCr) and lipids at 1.30 ppm across the
five different tumour types.
(TIF)
S11 Fig. Correlation of tGlut (glutamate + glutamine) content and lipid signals at 1.30ppm
across the five different tumour types.
(TIF)
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